These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36441343)

  • 1. Cerebrospinal fluid/serum albumin quotient (Q-Alb) is not increased in Alzheimer's disease compared to neurological disease controls: a retrospective study on 276 patients.
    Giacopuzzi Grigoli E; Solca F; Milone I; Aiello EN; Dubini A; Ratti A; Torresani E; Poletti B; Ticozzi N; Ciusani E; Silani V; Verde F
    Neurol Sci; 2023 Feb; 44(2):709-713. PubMed ID: 36441343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson's Disease Patients.
    Liguori C; Olivola E; Pierantozzi M; Cerroni R; Galati S; Saviozzi V; Mercuri NB; Stefani A
    CNS Neurol Disord Drug Targets; 2017; 16(3):339-345. PubMed ID: 27934563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression of Blood-Brain Barrier Leakage in Patients with Alzheimer's Disease as Measured with the Cerebrospinal Fluid/Plasma Albumin Ratio Over Time.
    Musaeus CS; Gleerup HS; Hasselbalch SG; Waldemar G; Simonsen AH
    J Alzheimers Dis Rep; 2023; 7(1):535-541. PubMed ID: 37313491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal Fluid/Plasma Albumin Ratio as a Biomarker for Blood-Brain Barrier Impairment Across Neurodegenerative Dementias.
    Musaeus CS; Gleerup HS; Høgh P; Waldemar G; Hasselbalch SG; Simonsen AH
    J Alzheimers Dis; 2020; 75(2):429-436. PubMed ID: 32280104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in CSF sPDGFRβ level and their association with blood-brain barrier breakdown in Alzheimer's disease with or without small cerebrovascular lesions.
    Lv X; Zhang M; Cheng Z; Wang Q; Wang P; Xie Q; Ni M; Shen Y; Tang Q; Gao F;
    Alzheimers Res Ther; 2023 Mar; 15(1):51. PubMed ID: 36915135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Vascular Risk Factors on Blood-Brain Barrier and Cerebrospinal Fluid Biomarkers Along the Alzheimer's Disease Continuum: A Retrospective Observational Study.
    Ricci F; Martorana A; Bonomi CG; Serafini C; Mercuri NB; Koch G; Motta C
    J Alzheimers Dis; 2024; 97(2):599-607. PubMed ID: 38160356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
    Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF
    Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid lactate levels along the Alzheimer's disease continuum and associations with blood-brain barrier integrity, age, cognition, and biomarkers.
    Zebhauser PT; Berthele A; Goldhardt O; Diehl-Schmid J; Priller J; Ortner M; Grimmer T
    Alzheimers Res Ther; 2022 Apr; 14(1):61. PubMed ID: 35473756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease.
    Baldeiras I; Santana I; Leitão MJ; Vieira D; Duro D; Mroczko B; Kornhuber J; Lewczuk P
    Alzheimers Res Ther; 2019 Jan; 11(1):2. PubMed ID: 30611311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood-Brain Barrier Breakdown in Relationship to Alzheimer and Vascular Disease.
    Lin Z; Sur S; Liu P; Li Y; Jiang D; Hou X; Darrow J; Pillai JJ; Yasar S; Rosenberg P; Albert M; Moghekar A; Lu H
    Ann Neurol; 2021 Aug; 90(2):227-238. PubMed ID: 34041783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Relationship between Markers of Inflammation and Degeneration in the Central Nervous System and the Blood-Brain Barrier Impairment in Alzheimer's Disease.
    Muszyński P; Kulczyńska-Przybik A; Borawska R; Litman-Zawadzka A; Słowik A; Klimkowicz-Mrowiec A; Pera J; Dziedzic T; Mroczko B
    J Alzheimers Dis; 2017; 59(3):903-912. PubMed ID: 28697565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
    Haris M; Yadav SK; Rizwan A; Singh A; Cai K; Kaura D; Wang E; Davatzikos C; Trojanowski JQ; Melhem ER; Marincola FM; Borthakur A
    Neuroimage Clin; 2015; 7():598-604. PubMed ID: 25844314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood-Brain Barrier Dysfunction and Aβ42/40 Ratio Dose-Dependent Modulation with the ApoE Genotype within the ATN Framework.
    Toniolo S; Di Lorenzo F; Bernardini S; Mercuri NB; Sancesario GM
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
    Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
    Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
    Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C
    J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different Inflammatory Signatures in Alzheimer's Disease and Frontotemporal Dementia Cerebrospinal Fluid.
    Boström G; Freyhult E; Virhammar J; Alcolea D; Tumani H; Otto M; Brundin RM; Kilander L; Löwenmark M; Giedraitis V; Lleó A; von Arnim CAF; Kultima K; Ingelsson M
    J Alzheimers Dis; 2021; 81(2):629-640. PubMed ID: 33814444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood-brain barrier permeability of the demented elderly as studied by cerebrospinal fluid-serum albumin ratio.
    Wada H
    Intern Med; 1998 Jun; 37(6):509-13. PubMed ID: 9678683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated CSF angiopoietin-2 correlates with blood-brain barrier leakiness and markers of neuronal injury in early Alzheimer's disease.
    Van Hulle C; Ince S; Okonkwo OC; Bendlin BB; Johnson SC; Carlsson CM; Asthana S; Love S; Blennow K; Zetterberg H; Scott Miners J
    Transl Psychiatry; 2024 Jan; 14(1):3. PubMed ID: 38182581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium.
    Somers C; Struyfs H; Goossens J; Niemantsverdriet E; Luyckx J; De Roeck N; De Roeck E; De Vil B; Cras P; Martin JJ; De Deyn PP; Bjerke M; Engelborghs S
    J Alzheimers Dis; 2016 Aug; 54(1):383-95. PubMed ID: 27567807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.